EDNRA and Pulmonary arterial hypertension associated with portal hypertension: Combination therapy with intravenous Iloprost and oral Bosentan, a dual endothelin-1 receptor antagonist, might extend the survival of selected patients suffering from POPH and recurrent right heart failure.[42] Bosentan has been shown to be effective in the treatment of POPH.